{"id":9606,"date":"2025-01-30T07:57:28","date_gmt":"2025-01-30T12:57:28","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=9606"},"modified":"2025-01-30T19:38:05","modified_gmt":"2025-01-31T00:38:05","slug":"az-daiichis-enhertu-bags-7th-fda-green-light-first-for-breast-cancer","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/az-daiichis-enhertu-bags-7th-fda-green-light-first-for-breast-cancer\/","title":{"rendered":"AZ, Daiichi\u2019s Enhertu Bags 7th FDA Green Light, First For Breast Cancer"},"content":{"rendered":"<p>Enhertu, the first antibody-drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, has received a seventh nod from the FDA, only 11 days after Datroway, the second ADC developed by the partners, was approved for cancer therapy.<\/p>\n<p>Enhertu is the first HER2-directed medication to get regulatory approval in the U.S. for patients whose breast cancer has progressed after receiving one or more endocrine treatments and have extremely low HER2 levels.<\/p>\n<p>After Enhertu made history in 2022 as the first therapy for HER2-low metastatic breast cancer, the medical world wondered how low Enhertu could actually go.<\/p>\n<p>The green light not only makes Enhertu the first therapy for patients whose tumors exhibit a lower level of the HER2 protein biomarker, but it also elevates Enhertu up another level in the treatment queue for those suffering from HER2-low metastatic breast cancer. It may now be utilized after one or more unsuccessful endocrine treatments.<\/p>\n<p>The FDA breakthrough is based on the findings of the DESTINY-Breast06 study, in which Enhertu demonstrated a 36% decrease in the likelihood of illness progression or mortality compared to chemotherapy. Patients who received Enhertu had an average progression-free survival of 13.2 months, whereas those who received chemotherapy had a median progression-free lifespan of just over 8 months. Of the patients who received Enhertu, 63% showed a full or partial response to treatment, compared to just under 35% of the patients who received chemotherapy.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\n\u201cEndocrine therapy is typically used in the initial treatment of HR-positive metastatic breast cancer and following progression, subsequent chemotherapy is associated with poor outcomes,\u201d Aditya Bardia, M.D., the trial investigator, stated in a release. He added that Enhertu brings with it a potentially new standard in terms of healthcare for patients with this form of the disease after endocrine therapy.<\/p>\n<p>Enhertu was originally authorized in 2019 to treat individuals with severe or metastatic HER2-positive breast cancer who had previously failed on at least two earlier therapies. In 2019, AZ announced a $6.9 billion investment in Enhertu, paying $1.35 billion upfront to study and market the therapy outside of Japan. According to the companies, AZ is required to pay Daiichi $175 million as a milestone payment after Tuesday&#8217;s approval.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nIn 2022, Enhertu became a massive success, and in the first three quarters of 2024, it produced $2.7 billion, an increase of almost $1 billion from the first three quarters of the previous year.<\/p>\n<p>Earlier this month, the firms received FDA clearance for Datroway, which is used to treat HR-positive, HER2-negative breast cancer for people who have already had endocrine-based treatment and chemotherapy. AZ agreed to become an affiliate for the TROP-2 targeted ADC in a transaction worth $5 billion, with $1 billion paid upfront. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Enhertu, the first antibody-drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, has received a seventh nod from the FDA, only 11 days after Datroway, the second ADC developed by the partners, was approved for cancer therapy. Enhertu is the first HER2-directed medication to get regulatory approval in the U.S. for patients whose breast cancer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9607,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[],"class_list":{"0":"post-9606","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-regulatory"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/9606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=9606"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/9606\/revisions"}],"predecessor-version":[{"id":9608,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/9606\/revisions\/9608"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/9607"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=9606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=9606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=9606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}